GENSCRIPT BIO (01548) Surges Over 8% in Morning Trading Following Lilly's $70 Billion In Vivo CAR-T Acquisition

Stock News04-21

GENSCRIPT BIO (01548) saw its shares rise more than 8% during the morning session. At the time of writing, the stock was up 6.84%, trading at HKD 14.68, with a turnover of HKD 107 million. The surge follows the official announcement by Eli Lilly of its acquisition of Boston-based biotechnology firm Kelonia for an upfront payment of $3.25 billion and a total potential consideration of up to $70 billion. Kelonia's core technology, iGPS, is an in vivo CAR-T platform based on a modified lentiviral vector. Guotai Haitong Securities noted that in vivo CAR-T technology offers advantages such as simplified manufacturing, improved accessibility, and strong platform extensibility, and remains optimistic about its potential as a key direction for next-generation cell therapies. Public information shows that Legend Biotech's in vivo CAR-T project, LVIVO-TaVec100 (a CD19/CD20 bispecific in vivo CAR-T generating agent), initiated a Phase I IIT clinical trial in May 2025. The bispecific targeting strategy in its design provides a more differentiated advantage and may reduce the risk of tumor immune escape due to single antigen loss.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment